FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available.
Young
Donna
D
D026683:Advisory Committees / Q000331:legislation & jurisprudence; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry / Q000331:legislation & jurisprudence; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors